GlassScriptPhysician profile
Keshav Kukreja
NPI 1104274620
$4,263.53
in general payments reported to CMS, 2019-2025
27 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $305 · 2022: $434 · 2023: $1,065 · 2024: $1,132 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,524.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,546.89 | 2022-2025 | |
| Janssen Biotech, INC. | $520.11 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $402.84 | 2022-2025 | |
| Olympus Corporation of The Americas | $304.83 | 2020 | |
| Phathom Pharmaceuticals, INC. | $192.21 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $150.52 | 2024-2025 | Rezdiffra, Resmetirom |
| Medical Device Business Services, INC. | $147.58 | 2023 | Linx Reflux Management System |
| Medtronic, INC. | $128.05 | 2022-2023 | Endoflip |
| Pfizer INC. | $118.73 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $96.52 | 2022 | |
| Boston Scientific Corporation | $88.22 | 2023 | Spyglass |
| Fujifilm Healthcare Americas Corporation | $79.37 | 2023-2025 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $66.01 | 2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $60.86 | 2022-2025 | Ocaliva |
| Novo Nordisk INC | $55.05 | 2025 | Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $49.03 | 2023-2024 | Zeposia |
| Lucid Diagnostics INC. | $47.01 | 2023 | |
| Ardelyx, INC. | $45.05 | 2025 | Ibsrela |
| Mauna Kea Technologies, INC. | $24.72 | 2024 | |
| Aimmune Therapeutics, INC. | $21.45 | 2024 | |
| Ferring Pharmaceuticals INC. | $20.77 | 2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $19.68 | 2022 | |
| Braintree Laboratories, INC. | $16.72 | 2024 | Sutab, Suflave |
| Evoke Pharma, INC. | $16.27 | 2023 | Gimoti |
| Gilead Sciences, INC. | $16.19 | 2023 | |
| Vivus LLC | $14.93 | 2024 | Pancreaze |
| Ethicon US, LLC | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keshav Kukreja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.